Abstract:Coined three decades ago, the term aptamer and directed evolution have now reached their maturity. The concept that nucleic acid could modulate the activity of target protein as ligand emerged from basic science studies of viruses. Aptamers are short nucleic acid sequences capable of specific, high-affinity molecular binding, which allow for therapeutic and diagnostic applications. Compared to traditional antibodies, aptamers have several advantages, including small size, flexible structure, good biocompatibility, and low immunogenicity. In vitro selection method is used to isolate aptamers that are specific for a desired target from a randomized oligonucleotide library. The first aptamer drug, Macugen, was approved by FDA in 2004, which was accompanied by many studies and clinical investigations on various targets and diseases. Despite much promise, most aptamers have failed to meet the requisite safety and efficacy standards in human clinical trials. Amid these setbacks, the emergence of novel technologies and recent advances in aptamer and systematic evolution of ligands by exponential enrichment (SELEX) design are fueling hope in this field. The unique properties of aptamer are gaining renewed interest in an era of COVID-19. The binding performance of an aptamer and reproducibility are still the key issues in tackling current hurdles in clinical translation. A thorough analysis of the aptamer binding under varying conditions and the conformational dynamics is warranted. Here, the challenges and opportunities of aptamers are reviewed with recent progress.

Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems

Advances In The Development Of Aptamer Drug Conjugates For Targeted Drug Delivery

Advances in the Development of Aptamer Drug Conjugates for Targeted Drug Delivery.

Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery

Recent advances in aptamer-based targeted drug delivery systems for cancer therapy

Recent Progress In Aptamer Discoveries And Modifications For Therapeutic Applications

Molecular Aptamers for Drug Delivery

Recent Developments in Protein and Cell-Targeted Aptamer Selection and Applications.

Smart ligand: Aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy

Advances in Aptamer Screening and Drug Delivery

Oligonucleotide aptamers: Recent advances in their screening, molecular conformation and therapeutic applications

Aptamer-functionalized nanoparticles for targeted drug delivery in cancer therapy

Progress in Aptamer-Mediated Drug Delivery Vehicles for Cancer Targeting and Its Implications in Addressing Chemotherapeutic Challenges.

Development of Better Aptamers: Structured Library Approaches, Selection Methods, and Chemical Modifications

Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy

Aptamers: Promising Reagents in Biomedicine Application

Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy

Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine

Current Status and Challenges of Aptamers Screening and Optimization.

Aptamers As Theranostic Agents: Modifications, Serum Stability and Functionalisation

Recent Progress and Opportunities for Nucleic Acid Aptamers